Benlysta's Broad Label Prepares The Way For A New Blockbuster
Executive Summary
The broad labeling that FDA approved for Benlysta (belimumab), the breakthrough lupus drug Human Genome Sciences Inc. shares with GlaxoSmithKline PLC, could position the biologic for widespread reimbursement.You may also be interested in...
Your First Drug's Approved and Launched...Now What?
FDA new drug approvals are making a comeback, and a group of biopharma first-timers are leading the way. To understand the challenges they face in the transition from discovery to commercialization, IN VIVO looked at 50 companies spanning the past 10 years. Finally reaching the US market might be a biotech's defining moment, but for those who build to last, there could be more rewards beyond that first approval.
Industry Ignored In Dispute Over UK Retailer’s ‘Weight Management’ Claim
Despite being defended by four industry representative bodies, UK health food retailer Holland & Barrett has been rapped for its use of “weight management” as a product category on its consumer-facing website by the country's Advertising Standards Authority.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports